Skip to main content

Advertisement

Table 1 Summary of responses seen in 26 patients with refractory hematological malignancies treated with haploidentical PBSC infusions [[15]]

From: Cellular immunotherapy for refractory hematological malignancies

Malignancy Complete response Partial response Transient response Total response
AML 3/13 (23%) 0/13 (0%) 7/13 (54%) 10/13 (77%)
NHL 2/6 (33%) 2/6 (33%) 0/6 (0%) 4/6 (66%)